BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab cash
Cash and short-term investments held at the end of each period.
BioNexus Gene Lab's cash was $1.23M at Jun 30, 2026. For fiscal 2025 it was $2.38M, down 17.4% from the year before. The highest annual figure on record is $4.52M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.38M | -17.4% |
| FY2024 | Dec 31, 2024 | $2.89M | -36.1% |
| FY2023 | Dec 31, 2023 | $4.52M | +113.2% |
| FY2022 | Dec 31, 2022 | $2.12M | -0.2% |
| FY2021 | Dec 31, 2021 | $2.12M | -23.8% |
| FY2020 | Dec 31, 2020 | $2.79M | +224.5% |
| FY2019 | Dec 31, 2019 | $859.08K | -31.8% |
| FY2018 | Dec 31, 2018 | $1.26M | +50.2% |
| FY2017 | Dec 31, 2017 | $839.15K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.23M | -19.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.34M | -36.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.38M | -17.4% |
| Q3 FY2025 | Sep 30, 2025 | $1.15M | -72.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.54M | -71.6% |
| Q1 FY2025 | Mar 31, 2025 | $2.09M | -52.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.89M | -36.1% |
| Q3 FY2024 | Sep 30, 2024 | $4.14M | -32.7% |
| Q2 FY2024 | Jun 30, 2024 | $5.41M | +207.8% |
| Q1 FY2024 | Mar 31, 2024 | $4.44M | +124.9% |
| Q4 FY2023 | Dec 31, 2023 | $4.52M | +113.2% |
| Q3 FY2023 | Sep 30, 2023 | $6.15M | +320.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.76M | +31.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.97M | +7.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.12M | -0.2% |
| Q3 FY2022 | Sep 30, 2022 | $1.46M | -14.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.34M | -9.6% |
| Q1 FY2022 | Mar 31, 2022 | $1.84M | -25.5% |
| Q4 FY2021 | Dec 31, 2021 | $2.12M | -23.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.70M | -22.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.48M | +15.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.47M | +77.2% |
| Q4 FY2020 | Dec 31, 2020 | $2.79M | +224.5% |
| Q3 FY2020 | Sep 30, 2020 | $2.19M | +124.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.29M | +12.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.40M | +133.8% |
| Q4 FY2019 | Dec 31, 2019 | $859.08K | -31.8% |
| Q3 FY2019 | Sep 30, 2019 | $977.15K | -31.0% |
| Q2 FY2019 | Jun 30, 2019 | $1.14M | +35.9% |
| Q1 FY2019 | Mar 31, 2019 | $597.46K | – |
| Q4 FY2018 | Dec 31, 2018 | $1.26M | – |
| Q3 FY2018 | Sep 30, 2018 | $1.42M | – |
| Q4 FY2017 | Dec 31, 2017 | $839.15K | – |
See a number that looks wrong?